SecBot SecBot

CATX

Perspective Therapeutics, Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0000728387 Biotech & Drug Discovery
$1.25 −0.36 (−22.05%)
Oct 26 4:00 PM ET · prev $1.61
Market cap
$258.0M
Micro cap
Consensus
Buy
90% Buy or better · 21 analysts
Median target
$13.00
+936% · range $5.00–18.00
1 year
−59.5%
from $3.10 · Oct 27
30 days
−49.8%
from $2.50
52-week range
$1.25–5.65
at the low
Avg volume 20D
2.06M
Oct 23 spike 5.60M
Short interest
16.57M
≈14.5% of shares · −27.3%
Days to cover
5.5
at average volume
Insider net
−$1.6M
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 3 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 7/9
Strongest BULLISH Perspective Therapeutics reported updated interim Phase 1/2a data for [212Pb]VMT-α-NET (bamzireotide…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $1.6M.

  • InstitutionsBULLISH

    Q2 2026: 31 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    19 of 21 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.294 → −$0.245 over 90 days. 6 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −27.3% to 16.57M shares. 5.5 days to cover, ≈14.5% of shares.

  • TrendDOWNTREND

    54% below its 50-day average. New closing low $1.25 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD9,494,152$32.4M
STATE STREET CORPADD6,051,771$20.6M
GEODE CAPITAL MANAGEMENT, LLCADD2,458,673$8.4M
MORGAN STANLEYTRIM1,912,550$6.5M
GOLDMAN SACHS GROUP INCADD1,733,078$5.9M
VANGUARD PORTFOLIO MANAGEMENT LLCADD1,087,767$3.7M
DIMENSIONAL FUND ADVISORS LPDOUBLED1,074,071$3.7M
NORTHERN TRUST CORPADD791,774$2.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 90% rate it Buy or better
Strong Buy5Buy14Hold2Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +936%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 7, 2026BTIG
REITERATE
REITERATEBuy
Sep 18, 2026William Blair
INITIATE
INITIATEOutperform
Sep 15, 2026Wedbush
REITERATE
REITERATEOutperform
Aug 19, 2026BMO Capital
INITIATE
INITIATEOutperform
Aug 14, 2026B of A Securities
MAINTAIN
MAINTAINNeutral
Aug 11, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$1.6M
sold · 2 insiders
DateInsiderTypeValue
Sep 4, 2026
Lantheus Alpha Therapy, LLC
10%+ Owner
SELL$526.1K
Sep 3, 2026
Lantheus Alpha Therapy, LLC
10%+ Owner
SELL$250.9K
Sep 2, 2026
Lantheus Alpha Therapy, LLC
10%+ Owner
SELL$131.2K
Sep 1, 2026
Lantheus Alpha Therapy, LLC
10%+ Owner
SELL$111.6K
Sep 1, 2026
Lantheus Holdings, Inc.
10%+ Owner
SELL$111.6K
Aug 31, 2026
Lantheus Alpha Therapy, LLC
10%+ Owner
SELL$245.6K
Aug 31, 2026
Lantheus Holdings, Inc.
10%+ Owner
SELL$245.6K
Mar 2, 2026
Hunt Jonathan Robert
Chief Accounting Officer
AWARD90,000 sh

Earnings setup

Estimates
−$0.25
EPS estimate, this quarter
+16%
estimate change, 90 days
6↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.25-$0.31–-$0.22+1.0%$51.8K
Next Q-$0.26-$0.32–-$0.19-1.1%$56.0K
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
16,570,625
shares short
-27.3%
vs prior settlement
5.5
days to cover
≈14.5%
of shares outstanding
Trading halts
Oct 23, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 Trading halt
Halt Resumed: CATX — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-23T12:12:00.000Z | Resumed 2026-10-23T15:05:00.000Z
Oct 23, 2026 SEC
Perspective Therapeutics reported updated interim Phase 1/2a data for [212Pb]VMT-α-NET (bamzireotide navoxetan) in…
8-K — Impact 6/10
Oct 8, 2026 SEC
Perspective Therapeutics announced FDA Fast Track Designation for PSV359, its FAP-targeted alpha-particle therapy for…
8-K — Impact 6/10
Oct 2, 2026 Press
Perspective Therapeutics announced that data from its lapemelanotide zapixetar ([²¹²Pb]VMT01) program for metastatic…
Impact 3/10
Sep 14, 2026 SEC
Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate its targeted…
8-K — Impact 5/10
Sep 11, 2026 Press
Perspective Therapeutics announced that updated data on its [212Pb]VMT-α-NET program for neuroendocrine tumors (NETs)…
Impact 3/10
Sep 4, 2026 Insider
Lantheus Alpha Therapy, LLC sold 167,149 shares
10%+ Owner @ $3.15 ($526.1K)
Sep 3, 2026 Insider
Lantheus Alpha Therapy, LLC sold 80,783 shares
10%+ Owner @ $3.11 ($250.9K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 23, 2026
Trading halt
Halt Resumed: CATX — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-23T12:12:00.000Z | Resumed 2026-10-23T15:05:00.000Z
Oct 23, 2026
Trading halt
Trading Halt: CATX — T3 (News and Resumption Times)
Perspective Therapeutics, Inc. Common Stock | Market: NYSE | Code: T3 — News and Resumption Times
Oct 23, 2026
Trading halt
Trading Halt: CATX — T1 (News Pending)
Perspective Therapeutics, Inc. Common Stock | Market: NYSE | Code: T1 — News Pending
Oct 2, 2026
Announcement
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN…
Sep 30, 2026
Short interest
Short Interest: CATX down 27% to 16.6M shares
Settlement 2026-09-30 | Days to cover: 5.52 | ≈14.52% of shares outstanding (est.)

SecBot reports

12 filings · 12 press releases · 4 bullish · 0 bearish · 8 neutral
All CATX filing & press-release reports (24)